Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > iOS it possible???
View:
Post by okgonow on May 20, 2024 10:20am

iOS it possible???

Was looking at the Tillray forum and checked out their last NR

RE:New Press Release - Tilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis Rescheduling When Effective

It looks to me like the Tillray strategy to get into the US will be to buy their way in by M&A or takeover of a company that has the license needed to sell. 

that probably goes for the other Canadian Weed companies as well in a MPL CC they mentioned that they have been working on getting FDA/DEA licensing for many years. So if another Company wants in and they are not well into the process of applying for these licenses the earliest way to get there and quickly is to buy a company that had licensing--------I don't think any of the Canadian Pot companies can afford to purchase Jazz Pharma so that leaves only one company!?

Wondering if this was Pidducks and MPL boards plan all along????????


time will tell!

Comment by Solid1 on May 21, 2024 5:25am
Tilray is the dumping ground of failed companies. As far as I know, they are brewers after all ?
Comment by Solid1 on May 21, 2024 6:14am
And with Medmen they really hit the jackpot...  Tilray is amazing... maybe Tilray will take the new money and use it to service Medmen's creditors, then they can take it over completely.... I don't know 
Comment by alleyesonme on May 21, 2024 7:19pm
It's certainly interesting, Tilray raising 250m for acquisition's in corps set to benefit from the U.S rescheduling, first time comments in Q1 w.r.t valuation from Pidduck, close existing business relationship with Tilray, and presumably, the only Canadian Corp to be privileged in exporting medical to the U.S.. let's hope this share price can climb soon to avoid a takeover at 15c..IMO ...more  
Comment by Solid1 on May 22, 2024 4:03am
I have a feeling this has something to do with Medmen in the US. Medmen has about 411 million in debt and Tilray holds about 165 million in bonds, the difference is 246 million.... so it could fit... but I'm no expert... Only they can't get to Labs because (no debt) 
Comment by okgonow on May 22, 2024 9:06am
  Yes they need to buy another company that puts them even deeper in the red with another unprofitable buissness possible having to pay more millions in lawsuits etc. But if the whole world leagalizes pot at some point 15 years in the future they may eventually get to making more than they spend. unless they go titz up before then
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities